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Streptococcus agalactiae CAMP factor is a protein exotoxin that contains 226 amino 
acid residues and forms oligomeric pores on susceptible cell membranes and liposomes. In 
this study, fragments of CAMP factor were created and recombinantly expressed to 
identify functional domains that are involved in membrane binding, oligomerization, and 
membrane insertion. Altogether, six truncated forms of CAMP factor were created and 
assayed. CAMP1-113, CAMP1-170, CAMP57-226, and CAMP171-226 showed different levels of 
hemolytic activity. CAMP1-56 and CAMP114-226 did not show hemolytic activity or 
oligomerization ability, but showed binding ability. CAMP114-226 inhibited the hemolytic 
activity of wild-type CAMP factor, most likely through ‘one-sided’ oligomerization. From 
the comparison of these fragments, it emerges that the region between residues 57 and 113 
plays a crucial role in oligomerization and membrane insertion. The high binding 
efficiency of CAMP114-226 suggests this region has great responsibility on membrane 
binding. The hemolytically inactive fragments showed higher binding efficiency than some 
of the active fragments. For the hemolytic fragments, higher binding efficiency gave 
stronger hemolysis. These findings support that CAMP factor has different functional 
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Chapter 1 Introduction 
 
Membranes define the boundary of the basic biological unit, the cell. They also 
compartmentalize the various subcellular organelles, such as nuclei, chloroplasts, and 
mitochondria, in eukaryotes. Membranes function as the protective barriers for the cells. 
They are also involved in regulating the trafficking of materials between different 
organelles within cells and also the trafficking of materials between cells. The damage on 
membranes may lead to cell lysis and death.  For defensive purpose, certain organisms 
create toxins to damage the membanes of their invaders. Some organisms create toxins 
damaging target membranes to facilitate their growth and reproduction. 
1.1 Membrane-Damaging Proteins and Peptides 
Membrane-damaging proteins and peptides are represented in a range of organisms 
including humans, bacteria, insects, fungi, amoeba, and plants. They are classified into 
three groups according to their different membrane-damaging mechanisms: enzymatic 
toxins, detergent-like toxins, and pore-forming toxins. 
 
1.1.1 Enzymatic toxins  
Enzymatic toxins damage the membranes by enzymatically hydrolyzing the 
phospholipids that constitute the cell membrane bilayers (Figure 1.1). The subsequent 
physical changes might finally lead to the collapse of the membrane [1]. Enzymatic toxins 
exhibit phospholipase activity, such as the Clostridium perfringens α-toxin (phospholipase 
C) and Vibrio damsela hemolysin (phospholipase D). Some of them exhibit 
























































1.1.2 Detergent-like toxins 
These toxins permeabilize the membrane by a detergent-like (surfactant) activity that 
results in membrane solubilization or partial insertion of the toxin into the hydrophobic 
cores of target membranes, such as Staphylococcus aureus δ-toxin [4]. They are usually α-
helical shaped or would adopt helical structure in the membrane-bound state [5, 6]. 
 Two models of membrane disruption have been proposed for these toxins: the “carpet” 
model and the “barrel-stave” model (Figure 1.2). In the “carpet” model, the lytic peptides 
bind to the target membrane surface and cover it like a carpet, inserting in between the 
phospholipid head groups. When a threshold concentration has been reached, the resulting 
strain on the lipid packing results in temporary membrane permeation and finally 
disintegration of the membrane into micelles. In the “barrel-stave” model, the amphipathic 
α-helices of the toxin insert into the membrane and recruit more monomers to from 








Figure 1. 2: The “carpet” (to the left) and “barrel-stave” (to the right) models of 
membrane permeation by lytic-peptides.       
In the “carpet” model, the amphipathic peptides bind to the membrane surface with their 
hydrophobic sides and expose their hydrophilic sides to the solvent thereby distending the 
head group layer of the membrane (step A). When a threshold concentration has been 
reached, the ensuing membrane curvature strain leads to the disruption of membrane 
continuity and the formation of transient pores and micelles (B). In the `barrel-stave' model, 
the amphipathic peptides first assemble in the surface of the membrane (A), then insert into 
the lipid core of the membrane following recruitment of additional monomers. Their 
hydrophobic sides interact with the core of the membrane lipids, and their hydrophilic 
sides face the aqueous pore (B) [7]. 
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1.1.3 Pore-forming toxins 
This group comprises the majority of the membrane-damaging proteins and peptides. 
They are produced by a number of organisms, such as bacteria, plants, fungi, primitive 
metazoans, insects and humans [8] (Table 1.1). CAMP factor is also from this group.    
Table 1. 1 Examples of pore-forming proteins and peptides. 
 
Origin Target Examples 
Man Bacteria Complement [9] 
Man Man Complement [9] 
Bacteria Man Streptococcus agalactiae CAMP factor [10, 11] 
Bacteria Bacteria Colicins [2] 
Bacteria Insects Bacillus thuringiensis toxins [12, 13] 
Insects Bacteria Cecropin [14, 15] 
Insects Man Melittin [16] 
Ameoba Bacteria Amoebapore [17] 
Fungi Bacteria Alamethicin [18] 
 
 
1.1.3.1 The general mechanism of pore-forming toxins (PFTs) 
The toxins are produced and released primarily as water soluble monomeric proteins 
which bind to the target cell membranes [1]. The binding of PFTs to membranes usually 
occurs via specific receptors, such as cholesterol and glycosylphosphatidylinositol (GPI)-
anchored proteins [19-22]. The membrane bound PFTs oligomerize and from a pre-pore 
complex, which undergoes significant conformational change that leads to the insertion of 
the oligomer into the lipid matrix. Concomitantly, the hydrophobic surfaces of the toxin 
proteins are exposed to the lipids and a transmembrane pore is formed that is lined by 
 5
hydrophilic residues (Figure 1.3). These pores vary in size, from 1-2nm with S aureus α-
toxin [23-25], to 25-30nm in perfringolysin O [26, 27]. Both ring- and arc-shaped pores 
have been observed by electron microscopy [23, 24]. 
 
 




Figure 1. 3: The general mechanism of pore formation.  
Toxins are released as water-soluble monomers (1), bind to membrane, often via specific 
receptors (2), oligomerize with other membrane bound toxins and form the pre-pore 
complex (3), the complex undergoes conformational changes, and inserts into the 




1.1.4 Biological function of PFTs 
PFTs are secreted by various bacteria to disrupt and damage the host cell membranes. 
For some non-pathogenic bacteria, such as Bacillus alvei and Bacillus cereus, they help to 
maintain their saprophytic life style [20]. For pathogenic bacteria, these toxins are 
important as virulence factors, which contribute to bacterial survival and spread in the host 
organisms. Many invasive bacteria when rendered unable to produce their PFTs exhibit 
reduced or abolished virulence [28-31]. During infection of host organisms, pore formation 
causes osmotic imbalance that consequently leads to cell swelling, lysis, and death [2]. 
Lysis of the white blood cells may reduce the host’s antibacterial immune response and 
promote the spread of bacteria. The transmembrane pore also provides access to essential 
intracellular nutrients to facilitate bacterial growth and reproduction [32]. 
 
1.1.5 Prototypical PFTs 
PFTs exist in two distinct stable states. Initially, they are water-soluble and 
monomereic; after membrane binding, they undergo a significant conformational change 
that converts them to the oligomeric membrane-inserted and lipophilic form [33, 34].  
While the three-dimentional structure of the monomeric forms of several PTFs are known, 
only very few oligomer structures have been solved by crystallography or characterized in 
sufficient details with other means.  The following sections describe well-studied PFTs that 





1.1.5.1 Staphylococcus aureus α-hemolysin 
α-hemolysin is released by Staphylococcus aureus as a 33 kDa water-soluble monomer 
which forms a heptameric β-barrel transmembrane pore on the surface of susceptible cells, 
leading to cell lysis and death. There is only the heptamer crystal structure of α-hemolysin 
solved, and only the monomer structure for leukocidin F (LukF) (Figure 1.4) [24, 35]. 
However, both toxins are sufficiently similar for us to consider the two crystal structures as 
complementary models of a common monomer and oligomer structure [36]. LukF is very 
similar in structure with the α-hemolysin monomer when it is situated within the heptamer 
pore (Figure 1.4B, C), except for the stem domains and the “amino latch” structure [37]. In 
the LukF, the amino latch is packed closely towards its β-sandwich core, whereas in the α-
hemolysin, it reaches to its adjacent protomer and forms a strong contact. The stem domain 
is folded in close proximity to the β-sandwich core to maintain the monomer’s water 
solubility. In the heptamer, the stem domain is unfolded and it inserts into the membrane 
with one β-hairpin. The amino latch has an extended conformation when the monomer 
converts to the pore-forming conformation. 
The complete four-step performing process of α-hemolysin is based upon the two 
previously described structures:  
1. α-hemolysin is secreted by S aureus as a water-soluble monomer with its stem 
      domain folded. 
2. The toxin monomers move towards host cells and bind to their membranes     
without significant conformational change. 
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3. The bound monomers oligomerize to each other with the N-terminal amino latch. 
Engaging in key inter-monomer interaction. A non-lytic heptamer is formed on the 
cell surface. 
4. The pre-stem domains from the non-lytic heptamer unfold and insert into the 
membrane. Each monomer contributes one β-hairpin, which lines the 
transmembrane portion of the channel. The membrane-inserted form of the 











       
                             A:  Leukocidin F                                     B:  α-hemolysin protomer       
 
             C: α-hemolysin heptamer side view                             D: Top view of heptamer 
 
Figure 1. 4: Ribbon representation of Leukocidin F and α-hemolysin. 
Leukocidin F monomer (A), the α-hemolysin protomer of its membrane inserted heptamer 
(B), the side view (C), and top view (D) of α-hemolysin heptamer [36, 37]. 
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1.1.5.2 Cholesterol-Dependent Cytolysins  
Cholesterol-Dependent Cytolysins (CDCs) constitute the largest family PFTs, and they 
are also one of the most common bacterial toxins [2, 19, 38]. They exhibit some unique 
features: 
1. Their cytolytic activity shows an absolute dependence on the presence of the 
cholesterol in the membrane. 
2. They form very large oligomeric complexes containing up to 50 monomers and 
the resulting transmembrane pore can be up to 300Ǻ in diameter. 
3. Many mutagenesis and spectroscopic studies have suggested that in the water-
soluble monomeric form their pre-stem domains are folded into short α-helices. 
These helices are thought to convert to long transmembrane β-hairpins that insert 
into the membrane. 
 
Streptolysin O (SLO) and perfringolysin O (PFO) are the two most extensively 
characterized CDCs with respect to structure and function. The crystal structure of the 
monomeric, water-soluble PFO has been determined (Figure 1.5) [27], but there is no 
structure available for any CDC membrane-inserted oligomer yet. There are four domains 
in PFO as shown in Figure 1.5. In the water-soluble monomeric form, there are two 
transmembrane helices (TMHs) in domain 3. During the pore formation, these two α-






Figure 1. 5: Ribbon representation of water-soluble form of PFO.  
Domains 1-4 are denoted (D1-D4) on the Figure. The location of TMH1 and TMH2 are 
colored in red and green, respectively.  
 
1.2 CAMP factor 
CAMP factor is an extracellular protein toxin secreted by several Streptococcus species, 
such as Streptococcus agalactiae (S. agalactiae).  S. agalactiae CAMP factor has 226 
amino acid with a mass of 25 kDa [43]. It is the toxin studied in this project. 
 
1.2.1 CAMP reaction 
CAMP factor derives its name from the CAMP reaction, which was first described in 
1944 by Christie, Atkins, and Munch-Petersen. The term CAMP reaction was initially 
applied only to the synergistic hemolytic reactions between S. aureus and group B 
streptococci [44]. During the last few years, this term has also been used to describe the 
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synergistic lysis of red blood cells in the presence of exosubstances produced by 
microorganisms growing adjacent to each other on the surface of blood agar [45]. 
The CAMP reaction has been widely used as a diagnostic method to identify S. 
agalactiae. The nutrient sheep agar plate is used in this procedure. S. aureus, which 
produces sphigomyelinase, and the putative strains of S agalactiae are streaked across the 
plate at right angles, close but not touching each other. After incubation, if CAMP factor 
was produced by the strain, a distinct hemolytic zone would develop in the adjoining area 




Figure 1. 6: A blood agar plate used in CAMP reaction after incubation at 37oC for 
24 hours.  
The vertical streak is sphingomyelinase-producing S aureus strain. Strain 1, Enterococcus 
faecalis; Strain 2, Streptococcus salivarius; Strain 3, S agalactiae; Strain 4, Enterococcus 







1.2.2 Characterization of CAMP factor 
Despite the wide application of the CAMP reaction for decades, little was know about 
the structure and function of CAMP factor. CAMP factor has no enzymatic activity to 
change membrane content [43]. It causes lysis of sphingomyelinase-treated red blood cells 
that contain at least 45mol% of sphingomyelin in the cell membrane, such as those of 
sheep (50mol%) and bovine (45mol%) erythrocytes [10, 44, 49]. Erythrocytes containing 
less than 30mol% sphingomyelin such as those of human (27mol%) and rabbit (19mol%) 
are not susceptible to CAMP factor lysis after sphingomyelinase treatment. However, these 
cells may become susceptible to CAMP factor after treatment with phospholipase C [50, 
51]. Sphingomyelinase and phospholipase C convert sphingomyelin and 
phosphatidylcholine to ceramide and diacylglycerol, respectively (Figure 1.1). Therefore 
ceramide is not specifically required for the CAMP reaction. In contrast, cholesterol 
content in the membrane was shown to be critical for CAMP factor activity [11, 51]. 
Using electron microscopy (EM) and polyethylene glycol (PEG) osmotic protection 
studies, Lang and Palmer showed that CAMP factor formed pores on sphingomyelinase 
treated sheep erythrocytes [11]. Both regular round and irregular shaped pores were 
observed, and they varied in sizes, some of them with radii up to 12 nm [11]. The PEG 
protection experiments suggested that the hydrodynamic radius of these pores was between 
1.6nm and  2.7nm [11]. Receptors on the membrane have been shown to be important for 
the surface recognition and pore-formation, such as cholesterol for CDCs and 
glycosylphosphatidylinositol (GPI)-anchored proteins for aerolysin [1]. CAMP factor is 
known to bind to GPI-anchored proteins [22].  
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1.2.3 CAMP factor as virulence factor 
Neutralizing antibodies against CAMP factor were found in the sera of group B 
Streptococcus (GBS)-inoculated rabbits and cows [52]. CAMP factor was not found to be 
lethal to mice, but mice developed fatal septicaemia after injection with sub-lethal dose of 
GBS and repeated doses of purified CAMP factor [53, 54].  
CAMP factor was called protein B in some studies because it was reported to bind to 
the Fc arms of immunoglobulin (Ig) G and IgM [53]. Recent studies suggested that CAMP 
factor could not bind to human IgG [55]. 
 
1.3 Research objectives 
According to the previous studies, the pore-forming process of CAMP factor was 
suggested to be highly cooperative and to follow the general mechanism of PFTs [11, 56]. 
The objective of this project is to identify the functional regions which are responsible for 
S. agalactiae CAMP factor binding, oligomerization, and membrane insertion during the 
pore-forming process. The general strategy for characterization is to create truncated forms 
of CAMP factor by site-directed mutagenesis. These CAMP factor fragments were 







Chapter 2 Experimental procedures 
 
2.1 Reagents and equipments 
Primers, glutathione-agarose resin, glutathione, thrombin from human plasma, 
sphingomyelinase, bovine serum albumin (BSA) were purchased from Sigma-Aldrich 
(Oakville, ON). Dimethyl sulfoxide (DMSO) was from Caledon (Georgetown, ON), 
Glycerol was from EMD chemicals (Gibbstown, NJ). Fluorescein-5-maleide was bought 
from Biotium (Burlington, ON). Polyethylene glycol (PEG) 3500 was from Fluka 
(Germany). Escherichia coli (E. coli) XL1 Blue cells were from Clontech (Palo Alto, CA), 
E. coli BL21 (DE3) cells were from Novagen (Madison, WI).  All lipids were from Avanti 
Lipids (Alabaster, AL). Amplex Red cholesterol assay kit was from Invitrogen (Eugene, 
OR) Ampicillin, kanamycin and the rest of the chemicals were bought from Bioshop 
(Burlington, ON). Sheep red blood cells (citrated) were from Cedarlane Laboratories 
(Hornway ON). Deoxynucleoside triphosphates (dNTP) and Expanded High Fidelity PCR 
Kit were from Roche (Indianapolis, IN). Thrombin protease was purchased from 
Amercham Biosciences (Uppsala, Sweden). DNA markers, protein marker, and Restriction 
endonucleases (REs) ApaI, EcoRI, PsiI, SspI were purchased from MBI fermentas 
(Burlington, ON). P6DG gel was from BioRad (Richmond, CA). Nickel-nitrolotriacetic 
acid (Ni-NTA) resin and QIAprep spin miniprep kit were from Qiagen (Mississauga, ON). 
Superdex 75 (HR10/30) column was from Amersham (Piscataway, NJ).  
BioRad-Biological LP high performance liquid chromatography ( HPLC) system ( CA), 
Techne TC-512 PCR system ( Techne cambridge, UK), Spectramax-190 96-well plate 
reader (Molecular Devices, Sunnyvale, CA), Micromass Q-Tof Ultima GLOBAL mass 
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spectrometer (Waters, MA), emulsifier EmulsiFlex-C5 (Avestin), liposome extruder 
(Northern Lipids, Vancouver, BC) and QuantaMaster 4 fluorimeter (Proton technology Inc. 





Plasmid pET 30 a(+) with cloned methionine-free CAMP factor (CAMP M21L M107L) 
was used as the mutagenesis template. A DNA sequence for a 6X His-tag and thrombin 
cleavage site are located at the N terminus of the CAMP factor encoding gene. 
 
2.2.2 Recombination-based polymerase chain reaction (PCR) 
 
The mutagenesis procedure was based on the method developed by Howorka and 
Bailey where amino acid substitutions are introduced by polymerase chain reaction 
(PCR)[57]. In each PCR mutagenesis, four primers were used, including a pair of non-
mutagenic primers (pGEXfwd and pGEXrev) and a pair of mutagenic primers with 12 
overlapped base pairs. A single cysteine substitution was introduced here as well.  The 





Figure 2. 1: Mutagenic primer design: 
Each pair of the mutagenic primers has 12 overlapped base pairs (bp), shown in green and 
red. For each primer, there are 18 bases complementary to the plasmid template, shown as 
parallel to the template. The cysteine substitution (blue star) is introduced into the 
overlapped CAMP factor region (red). After in vivo recombination, specific parts of the 
CAMP factor gene would be deleted. There were 6 pairs of mutagenic primers designed as 
shown in Table 2.1. 
 
Initially, the template plasmid was linearized in separate digests with different 
restriction enzymes (REs). It was linearized with EcoRI for pGEXrev and forward 
mutagenic primer. SspI was used to other linearization. Secondly, the corresponding 
primers were used the PCR amplification (Table 2.2, and 2.3)).  Then the PCR products 








3. Mix & transform
4. in vivo recombination
 
Figure 2. 2 Schematic representation of recombination-based PCR mutagenesis:  
The non-mutagenic and mutagenic primer pairs are shown in red and blue, respectively. 1, 
the template plasmid is linearized separately using different restriction enzymes. 2, PCR.  
After the PCR, only the gene encoding the desired CAMP factor fragment would be 
amplified. 3, PCR products are mixed and transformed into XL-1 blue cells. Then the 











5’ TTTGCCCTAGTTATTTGCATTTTAG 3’ 







5’ ACTAAGTAATATTTGTATTTGTATTTTTCG 3’ 







5’ GTTGAATAATATTTGTATTTTTCG 3’ 






5’ TCTGGTAAATTAAAGACTTGCTTG 3’ 






5’ TGTACATAATATTTGTATTTTTCG 3’ 







5’ TCTGGTTGTTTTACTAGAGATAAAAAAG 3’ 





5’ AAGACGATAGTTACCGGATAAG 3’ 










Table 2. 2: Reagents used in the PCR. 
Deionized, autoclaved water 
 
40 μL 
Linearized template plasmid DNA 
 
1 μL (~ 1 μg) 
pGEXfwd/ pGEXrev 
 
1 μL (300nM, final) 
Reversed/ forward mutagenic primer 
 
1 μL (300nM, final) 
dNTP 
 
1 μL (200 μM, final) 
10X PCR buffer with MgCl2(15mM) 
 
5 μL 
Expand high fidelity DNA 






The mixtures were transferred into PCR tubes, vortexed and centrifuged briefly. The 
PCR were performed in a Techgene thermal cycle (Techne, Cambridge, UK) under the 
following conditions: 
 
Table 2. 3: PCR conditions. 
Pre-heating 
 
95oC 3 minutes 





95oC 30 seconds 
Annealing 
 
See Table 2.4 30 seconds 
Extension 
 
72oC 75 seconds 




72oC 10 minutes 
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Table 2. 4: Annealing temperatures for different PCRs. 












pGEXrev/ CAMP1-56fwd, pGEXfwd/ CAMP1-56rev, 




      The PCR products were analyzed by agarose gel electrophoresis for purity and size.  
The matching DNA fragments were mixed and transformed into XL-1 Blue competent 
cells.  
 
2.2.3 Plasmid extraction and verification 
 
Positive colonies were selected from LB agar plates containing kanamycin (20μg/mL) 
to inoculate 3 ml of sterilized LB media containing kanamycin (20μg/ml) and grown 
overnight with shaking (200 rpm)  at 37 oC. The plasmid was extracted from this culture 
using QIAprep Spin Miniprep Kit. The plasmid was digested with PsiI and ApaI to 
confirm its size by agarose gel electrophoretic analysis. The plasmid with desired size was 
sent for sequencing at University of Waterloo (Molecular Biology Core Facility) to ensure 
that the correct mutation had been introduced. The plasmid was transformed into E. coli 




2.3 Preparation of competent cells and transformation 
 
2.3.1 Preparation of E. coli XL-1 Blue heat-shock competent cells and heat-shock 
transformation 
 
1 ml of fresh overnight XL-1 Blue cell culture was diluted into 100 ml of sterilized LB 
broth and grown at 37oC with vigorous shaking to reach an optical density (OD600) of 0.4. 
The cells were harvested at 3000 revolutions per minute (rpm) for 15 minutes at 4oC. The 
supernatant was discarded and the cell pellet was resuspended in 1 ml LB and 1 ml 2X 
transformation and storage buffer (20 %( w/v) PEG 3350, 10% (v/v) dimethyl sulfoxide, 
50%(V/V) LB medium, 100mM MgCl2, pH6.5) on ice. These cells were aliquoted (100 μL) 
and stored at -80oC [58].  
For the transformation, 1 μL of PCR product was added to one aliquot of thawed cells 
and incubated on ice for 30 minutes. The cells were heat shocked by placing the tube in a 
42 oC water bath for 45 seconds and then cooled on ice for 3 minutes. Then the cells were 
transferred into 1 ml of SOC media and grown at 37oC with vigorous shaking for 1 hour. 
100 μL of the SOC culture was spread on LB agar plate with 20 μg/ml kanamycin. 
 
2.3.2 Preparation of E. coli BL21 (DE3) electroporation competent cells and 
transformation 
 
5 ml of fresh overnight BL21 (DE3) cell culture was diluted into 500 ml of sterilized 
LB broth and grown at 37oC with vigorous shaking to reach an OD600 of 0.6. The cells 
were collected by centrifugation at 3000 rpm for 15 minutes at 4oC. The supernatant was 
discarded and the cell pellet was resuspended in 500 ml of ice-cold 10% glycerol. The cells 
were harvested again following centrifugation and resuspended in 250 ml of ice-cold 10% 
glycerol. The cells were concentrated one more time by centrifugation and re-suspension in 
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2 ml of ice-cold 10% glycerol.The suspension was aliquoted ( 40 μL) and stored at -80oC 
[59].  
0.4 mL of plasmid DNA was added to one aliquot of thawed cells and electroporated in 
a BioRad cell pulser electroporation unit. Then the cells were transferred into 1 ml of SOC 
media (0.5% (w/v) yeast extract, 2% (m/v) tryptone, 10 mM NaCl, 2.5 mM KCl, 10 mM 
MgCl2, 20mM MgSO4, 20 mM glucose), and grown at 37oC with vigorous shaking for 1 
hour. 100 μL of the SOC  culture was spread on LB agar plate with 20 μg/ml kanamycin. 
 
2.4 Expression and purification of CAMP factor and its fragments 
 
Both CAMP factor and its fragments were expressed in E. coli BL21 (DE3) cells. A 
single colony with the plasmid of interest was picked and inoculated into 20 ml of Luria 
Bertani (LB) media containing antibiotics (100μg/ml ampicillin for CAMP factor, 20μg/ml 
kanamycin for mutants), and grown overnight at 37 oC with shaking (200 rpm). The 
overnight culture was diluted into 1 liter of LB media containing appropriate antibiotics, 
and grown at 30oC with vigorous shaking until the OD600nm reached 0.8. The protein 
expression was induced by adding isopropyl-1-thio-β-D-galactopyranoside (IPTG) to a 
final concentration of 1 mM. The cells were grown for an additional 4 hours at 37oC and 
harvested by centrifugation at 3000 rpm at 4 oC for 15minutes and stored at -20 oC 
overnight.  
For CAMP factor, the cell pellet was thawed on ice and resuspended in 15ml of 
phosphate-buffered saline (PBS) (16mM K2HPO4, 150 Mm NaCl, pH 7.2) containing 
protease inhibitor mixture (Sigma). For CAMP1-113, CAMP114-226, CAMP1-56, and CAMP1-
170, the cell pellets were resuspended in low concentration imidazole buffer (50 mM Tris, 
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250 mM NaCl, 50 mM imidazole, pH 7.5). For CAMP57-226 and CAMP171-226, the cell 
pellets were resuspended in lysis buffer (100mM NaH2PO4, 10 mM Tris, 6M guanidine 
hydrochloride, 10 mM imidazole, pH8). The cells were lysed by using an emulsifier at 
17000 psi. The lysates were centrifuged at 20000rpm for 15 minutes at 4oC, and the 
supernatants were used for the purification. All the purifications were performed at 4oC.  
CAMP factor fragments were purified using a Ni-NTA affinity column (5mL) and 
BioRad-Biological LP HPLC system were used for their purification. For CAMP1-113, 
CAMP114-226, CAMP1-56, and CAMP1-170, the lysates were injected to the column pre-
equilibrated with low concentration imidazole buffer. The column was washed with 10 
volumes of low imidazole buffer; the protein was eluted in gradient with high 
concentration imidazole buffer (50 mM Tris, 250 mM NaCl, 250 mM imidazole, pH7.5). 
For CAMP57-226 and CAMP171-226, the lysates were injected into the column pre-
equilibrated with lysis buffer. The column was washed with 10 volumn buffer A (100 mM 
NaH2PO4, 150 mM NaCl, 8 M urea, 20 mM imidazole, pH8) followed by 10 volume buffer 
B (50 mM NaH2PO4, 500 mM NaCl, 20 mM imidazole, pH8) and eluted in elution buffer 
(50 mM NaH2PO4, 500 mM NaCl, 250 mM imidazole pH7.5). These proteins were 
desalted using P6DG column pre-equilibrated with thrombin cleavage buffer (50 mM Tris, 
150 mM NaCl, 2.5 mM CaCl2, pH8.0). Thrombin was added to the protein solutions to a 
final concentration of 6 μg/ml and incubated for 30 minutes at room temperature. Then the 
protein solutions were run through P6DG column pre-equilibrated with Tris buffer (50 mM 
Tris, 150 mM NaCl, 1 mM EDTA, 5 mM DTT, pH7.5), CAMP factor fragments were 
collected and stored at -80oC with 10%(V/V) glycerol. The protein concentrations were 
determined by the Bradford method using bovine serum albumin (BSA) as a standard [60]. 
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CAMP factor was expressed as a glutathione-S-transferase fusion protein[11]. The 
purification method used was published by Guan and Dixon[61]. Briefly, the supernatant 
was run through a 5 ml glutathione-agarose column for 3 cycles. The column was washed 
with 10 volumes of PBST buffer (PBS buffer with 1% Triton X100), 4 volumes of PBS 
buffer and followed by 4 column volumes of thrombin cleavage buffer (50mM Tris, 
150mM NaCl, 2.5 mM CaCl2, pH 8) at room temperature. The column was suspended in 2 
ml of thrombin buffer containing 12 μg of thrombin and shaken gently at room temperature 
for 1 hour. The protein was eluted with thrombin cleavage buffer and stored at -80oC with 
10% (V/V) glycerol. 
 
2.5 Protein labelling 
 
Cysteine is a very strong nucleophile in a protein and also very rare in a protein, which 
makes it easily to be modified by a variety of reagents, such as maleimide. Maleimide 
reacts with the sulfhydryl group of cysteine with very high specificity, and its derivatives 
have been used to modify the cysteine residues in many proteins[62]. By combining site-
specific mutagenesis and cysteine modification techniques, the cysteine-free CAMP factor 
can be labelled by cysteine modification.   
The cysteine-substituted CAMP factor or CAMP factor fragments were exchanged into 
labelling buffer (50 mM Tris, 150 mM NaCl, 1 mM EDTA, pH7.5) with P6DG column at 
room temperature. A 10-fold molar excess of dye (fluorescein maleimde, or rhodamine 
maleimde) was dissolved in 10 μL of  DMSO. 500 μL of the protein was added to the dye 
and incubated in the dark at room temperature for 45 minutes. The unbound dye was 
removed by P6DG column with labelling buffer as eluant. 
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2.6 Hemolytic assay 
 
400 μL of sheep red blood cells were washed 5 times in HEPES buffer (20 mM HEPES, 
150 mM NaCl, pH 7.4) by centrifugation at 2000 rpm for 4 minutes. The cells were 
resuspended in HEPES buffer to 0.5% (V/V).  The cell suspension was incubated with 10 
mM MgCl2 and 50 milliunits/mL S. aureus sphingomyelinase (Sigma) at 37oC for 5 
minutes. Serial two-fold dilutions of CAMP factor and its fragments were prepared in 
microtiter plate in 20 μL of HEPES buffer. Then 180 μL of the sphingomyelinase-treated 
cells were added. Haemolytic activity was measured by the decrease in turbidity (OD650nm) 
using a 96-well plate reader over a period of 60 minutes at room temperature. 
 
2.7 Binding of CAMP factor fragments to erythrocyte membranes and 
chemical cross-linking 
 
The protein sample was added into the sphingomyelinase-treated ghost membranes, 
and incubated at 37oC for 45 minutes. The membranes were spun down at 13000 rpm for 
10 minutes and unbound proteins in the supernatant were discarded as supernatant. The 
membranes were resuspended and washed with Tris buffer (50mM Tris, 150 mM NaCl, 
pH7.5) by centrifugation for 3 times. The membrane pellet was dissolved in Tris buffer 
containing 10% (w/v) sodium deoxycholate. The dissolved membranes were analyzed by 
15% sodium dodecyl sulphate polyacrylamide gel electrophoresis (SDS-PAGE) to estimate 
the binding ability of the protein. 
Protein samples were incubated with liposomes (total lipids: 0.2 mg/ml) in HEPES 
buffer at 37oC for 30 minutes. The cross-linking reagent glutaraldehyde was added to 2.5 
mM and incubated for another 30 minutes. The reaction was stopped by adding 1M  Tris; 
to 0.1 M. Then the sample was analyzed for protein binding by 10% SDS-PAGE. 
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2.8 Hemolytic inhibition of CAMP factor fragments to CAMP factor 
 
The cell preparation was the same as the one described in section 2.5. Serial two-fold 
dilutions of CAMP factor fragments were prepared in a microtiter plate in 15 μL of 
HEPES buffer, 5 μL of diluted CAMP factor was added into each of them. Then 180 μL of 
cells were added, and the haemolytic activities were measured. 
 
2.9 Membrane binding competition of CAMP factor fragments to CAMP 
factor 
 
Except the possibility of being inhibited during oligomerization (described in section 
2.8), hemolysis could also be inhibited through competition for membrane binding 
receptors. Therefore, fragments that showed hemolytic inhibition would also have to be 
assayed for inhibition of CAMP factor binding. 
The ghost membranes were prepared as described in section 2.10. CAMP factor mutant 
(F109C) was labelled with fluorescein maleimide as described in section 2.5. Serial two-
fold dilutions of CAMP factor fragments were prepared in microcentrifuge tubes in 30 μL 
of HEPES buffer. To each dilution, 10 μL of diluted labelled CAMP factor F109C was 
added into each of them. Then 360 μL of membranes were added and incubated at 37 oC 
for 20 minutes. The membranes were spun down at 13000 rpm for 10 minutes and 
unbound proteins in the supernatant were discarded. The membranes were resuspended 
and washed with HEPES buffer by centrifugation at 13000 rpm for 10 minutes for 3 times. 
The membranes were dissolved in Tris buffer with 1% SDS, and the fluorescein 
fluorescence intensity was measured as described in section 2.13. 
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2.10 Preparation of erythrocyte ghost membranes  
 
400 μL of sheep red blood cells were osmotically lysed in 5 mM phosphate buffer 
(pH7.2), and the membrane were pelleted and washed by centrifugation at 13000 rpm for 
10 minutes. The washing was repeated several times until the membrane appeared white. 
The membranes were resuspended in HEPES buffer with 10 mM MgCl2. Then they was 
incubated with 50 milliunits/mL sphingomyelinase for 20 minutes at 37oC 
 
2.11 Preparation of liposomes 
 
Ceramide, cholesterol, and phosphatidylcholine were dissolved in 1 mL of chloroform 
at molar ratio of 40:45:15 to a final lipid concentration of 2 mg/ mL. The mixture was 
dried to a thin film under nitrogen gas in a round-bottom flask and dried for additional 3 
hours under vacuum. The lipids were hydrated at 45oC for 1 hour with HEPES buffer. The 
suspension was frozen at -20oC and thawed at 45oC, and then extruded through 
polycarbonate membranes with 100 nm pore size using a liposome extruder at 45 oC to 
form unilamellar liposomes. The extrution was repeated 20 times. The final lipid 
concentration was determined by using Amplex Red Cholesterol Assay Kit.  
2.12 Gel filtration 
 
A Superdex-75 gel filtration column (HR10/30) was equilibrated with Tris buffer 
(50mM Tris, 150 mM NaCl, pH7.5). The protein sample was exchanged to the same Tris 





2.13 Spectrofluorimetry  
 
Fluorescein-labelled protein was incubated with sphygomyelinase-treated ghost 
membranes and washed as described in section 2.10 but dissolved in Tris buffer containing 
1% (W/V) SDS. A membrane suspension without protein was used as blank. The 
fluorescence emission intensity was measured between 500 nm and 600 nm after excitation 
at 492 nm.  
 
2.14 Mass spectrometry 
 
A Micromass Q-Tof Ultima GLOBAL mass spectrometer was used for protein analysis 
by positive ion electrospray ionization mass spectrometry. The protein was exchanged into 
water using a P6DG column and mixed with acetonitrile/ water solution (0.2% formic acid) 
in a ratio of 1:1. The final protein concentration is approximately 5 μM. The data was 






















Chapter 3 Results and Discussion 
 
 
3.1 Construction of CAMP factor fragments 
 
All together, six fragments of CAMP factor were constructed: CAMP1-113, CAMP114-226, 
CAMP1-56, CAMP57-226, CAMP1-170, and CAMP171-226 (Figure 3.1).  
 
 
Figure 3. 1: Schematic representation of the fragments with wild type CAMP factor. 
The primers were designed based on plasmid pET30 a(+) encoding His-tagged CAMP 
factor. To obtain the optimal PCR products, different annealing temperatures were tested in 
small PCR mixture volume (5 μL in total). The PCR products generated by primer pair 
pGEXrev/ CAMP1-56fwd with different annealing temperatures were analyzed by 1% 
agarose gel electrophoresis shown as an example in Figure 3.1. The purest PCR product 
(Lane 4) was produced with annealing temperature was 57.4oC. Then the full scale (50μL) 
PCR was performed and used for transformation. All other PCRs were analyzed and with 






                                       1       2       3       4       M 
 
 
Figure 3. 2: PCR products from primer pair pGEXrev/ CAMP1-56fwd with different 
annealing temperatures: 
Lane1, 50oC; Lane 2, 52.5 oC; Lane 3, 55.4 oC; Lane 4, 57.4 oC. Lane M: Lambda 
DNA/EcoRI+HindIII Marker. 
 
After the PCR products were obtained, they were transformed into E.coli XL-1 Blue 
cells for in vivo recombination. Approximately 10 colonies were observed on each plate 
after 24 hours. Three colonies for each mutant were picked and grown for plasmid 
extraction. The plasmids were double digested by PsiI and ApaI, which gave two DNA 
fragments. The template CAMP factor plasmid was also double digested for comparison. 
Since specific regions of the gene were deleted, the lengths of the DNA fragments should 
be reduced accordingly. The DNA fragments were analyzed by 1% agarose gel 
electrophoresis.  Analyses for CAMP1-56 and CAMP57-226 plasmids are shown as examples 
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in Table 3.1 and Figure 3.3. The plasmids confirmed by RE digestion analyses were also 
confirmed by sequencing. 
 
Table 3. 1: The fragment lengths for template CAMP factor, CAMP1-56, and  
CAMP57-226 plasmids after double digestion by PsiI and ApaI. 
Plasmid 
 
Fragment length (bp) Deleted length (bp) 
Template CAMP factor 
plasmid 
3765, 2250 --- 
CAMP1-56 plasmid 
 
3765, 1740 510 
CAMP57-226 plasmid 
 
3765, 2082 168 
 
                                   M          1           2            3         4 
 
Figure 3. 3: Double digestion of plasmids. 
Lane M, Lambda DNA/EcoRI+HindIII Marker; Lane 1, template CAMP factor plasmid; 





3.2 Expression and Purification of CAMP factor fragments 
 
During the growth of cell cultures, cell samples were collected before IPTG induction 
and harvest; these samples were analyzed by SDS-PAGE to evaluate the protein 
expression.  
All the CAMP factor fragments were expressed with His-Tag affixed. For the 
purification of CAMP1-113, CAMP114-226, CAMP1-56, and CAMP1-170, these His-tagged 
proteins bound to the Ni-NTA affinity column were eluted by increasing imidazole 
concentration above 200 mM. They were collected and cleaved with thrombin. The CAMP 
factor fragments were obtained after the His-tag was separated by P6DG gel filtration. 
CAMP 1-113 is shown as an example in Figure 3.4.  
For the purification of CAMP57-226 and CAMP171-226, the same purification method as 
above was tried; however, there was only a very small amount of proteins were eluted from 
the column and they were not pure. The denatured purification method was tried, this 
protocol was expected to refold the protein on the column before the elution; however the 
protein was eluted in buffer A, which has very low imidazole concentration and was not 
expected to elute the proteins. Therefore, the protocol was modifid such that washing was 














   45kDa 
 
    
   35kDa 
 
 
        
       25kDa 
 
 
     
    18.4kDa 
 
Figure 3. 4: Expression and purification of CAMP1-113 in E. coli BL21 (DE3) analyzed 
by 15% SDS-PAGE. 
Lane M, protein marker; Lane 1, 2 and 3, thrombin-cleaved protein after P6DG gel 
filtration. Lane 4 and 5, E. coli protein extract before and after IPTG induction, 









3.3 Hemolytic activity of CAMP factor fragments 
 
Hemolytic activity assays were performed on all the six mutant fragments. CAMP1-113, 
CAMP57-226, CAMP1-170, and CAMP171-226 all showed activity, but much weaker comparing 
to intact CAMP factor. CAMP1-56 and CAMP114-226 did not show hemolytic activity (Figure 
3.5).  
For CAMP1-113, 50% hemolysis was achieved in 30 minutes with a concentration of 
400 μg/ml, comparing to CAMP factor achieved it in 15 minutes with a concentration of 1 
μg/ml (Figure 3.5 A). CAMP57-226 and CAMP1-170 could achieve 50% hemolysis in 15 
minutes at the concentrations of 12.5 μg/mL and 100 μg/mL, respectively. Within a longer 
period of time, these fragments lysed all the cells. CAMP171-226 showed hemolytic activity 
but could not lyse all the cells; 50% hemolysis was achieved by CAMP171-226 with a 
concentration of 400 μg/mL in 10 minutes, but lysis then did not progress any further 
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 (B) CAMP114-226  
Figure 3.5: Hemolytic titration of CAMP factor and fragments.  
Sheep red blood cells (0.5% (v/v), final) were treated with sphingomyelinase prior to the 
assay. Blood cells with no CAMP protein added were used as control. Hemolysis was 
assayed by the decrease in turbidity (OD650nm) for one hour with a time interval of 30 
second. (A) Hemolysis by CAMP1-113 at different concentrations. CAMP factor at 1 μg/mL 
is shown for comparison. (B) Hemolysis by CAMP114-226 at different concentrations. 
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3.4 Membrane binding of CAMP factor fragments 
 
Since the pore-formation is a cooperative process that includes binding, 
oligomerization, and insertion, the loss of pore formation activity could be the 
consequence of the failure of any of the three steps. 
Since CAMP114-226 and CAMP1-56 did not show hemolytic activity, they were tested for 
their ability to bind to cell membranes. These fragments were incubated with 
sphingomyelinase-treated sheep erythrocyte membranes, and then the membranes were 
analyzed by SDS-PAGE after being washed and dissolved. CAMP114-226 showed binding to 
the membrane (Figure 3.6 A). The binding of CAMP1-113 was also assayed to compare with 
CAMP114-226, however, binding was very weak even with increased concentration.  
CAMP1-170 and CAMP57-226 showed hemolytic activity, they were tested for binding 
ability as well (Figure 3.6 B). Although they showed same level of hemolytic activity, 
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Figure 3. 6: Binding of CAMP factor fragments to sphingomyelinase-treated sheep 
erythrocyte membranes. (A) Lane M, protein marker; Lane 1, CAMP114-226; Lane 2, 
CAMP114-226 incubated with cell membranes; Lane 3, cell membranes without CAMP 
factor protein; Lane 4, CAMP1-113; Lane 5, CAMP1-113 incubated with cell membranes. (B) 
Lane M, protein marker; Lane 1, CAMP1-170; Lane 2, CAMP1-170 incubated with cell 
membranes; Lane 3 and 6, cell membranes without CAMP factor protein; Lane 4, 
CAMP57-226; Lane 5, CAMP57-226 incubated with cell membranes 
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Due to the small size of CAMP1-56 and to interference by erythrocyte membrane 
proteins, its binding could not be reliably assessed by SDS-PAGE. Therefore, the binding 
was analyzed by spectrofluorimetry. To this end, one amino acid from CAMP1-56 (Serine54) 
was replaced with cysteine by site-specific mutagenesis, and the mutant cysteine was 
labelled by modification with fluorescein maleimide. The binding of labelled CAMP1-56 
to membranes was then observed from fluorescence emission after incubation and removal 
of unbound fragments by centrifugation (Figure 3.7). The binding efficiency was 
determined by comparing this emission intensity with the emission intensity from fragment 
solution without incubation with membrane. CAMP1-56 showed membrane-binding 
efficiency of 40.1 ± 1.1%. All the other fragments were also labelled and analyzed for 
binding efficiency: CAMP57-226 (101.2 ± 3.1%), CAMP1-113 (11.3 ± 0.8%), CAMP114-226 
(28.4 ± 0.8%), CAMP1-170 (14.8 ± 0.7%), and CAMP171-226 (32.5 ± 1.2%) (Appendix 2). 
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Figure 3.7: Fluorescence emission spectra of CAMP1-56 (5μM) labelled with 
fluorescein maleimde with excitation at 492 nm. 
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3.5 Hemolytic inhibition by CAMP factor fragments 
 
For PFTs, after binding to membranes, oligomerization is required before the pore-
formation. Both CAMP1-56 and CAMP114-226 showed the ability of binding to membrane, 
but neither of them has hemolytic activity. To determine their ability to oligomerize, 
chemical cross-linking assays were performed on liposomes, but there was no oligomer 
observed for either of them. This suggested that CAMP1-56 and CAMP114-226 lost their 
ability of oligomerize. Presumably, oligomerization involves two complementary surfaces 
of molecules (Figure 3.8). The loss of oligomerization could be the consequence of two 
possiblities: (1) Inactivation of both oligomerization surfaces; (2) loss of only one side. As 
shown in Figure 3.8 A, in the latter case the fragment molecules cannot oligomerize to 
each other; but when they are incubated with intact proteins, they could associate to them 
on one side and thereby stop the further oligomerization (Figure 3.8 B). This, in turn, 
should result in an inhibition of the activity of the intact toxin. 
Toxin fragmentIntact toxinToxin fragment
A B  
Figure 3. 8  Schematic representation of oligomerization inhibition. 
A, fragments cannot oligomerize each other even if only one oligomerization surface is 
inactivated. B, fragments that have lost one oligomerization surface may inhibit the 
oligomerization of intact protein molecules.  
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To detect if fragments lost all of their olgomerization ability, the hemolytic activities of 
complete CAMP factor incubated with each of them were measured. The time required by 
CAMP factor (1μg/mL) to reach 50% hemolysis of 0.5% (v/v) sphingomyelinase-treated 
cells was increased from 15 minutes to 30 minutes with addition of CAMP114-226 at a 
concentration of 16μg/mL (Figure 3.7). This suggested that, CAMP114-226 could 
oligomerize to one side of CAMP factor, which inhibits hemolysis. However, it did not 
rule out the possibility that CAMP114-226 inhibits hemolysis by intact CAMP factor by 
competing for binding sites.  
With further increasing concentrations of CAMP114-226 (32 and 64 μg/mL), the 
hemolysis was not reduced further. This might due to the association of the fragment with 
intact CAMP factor being weak and reversible, and the second molecule of CAMP factor 
can dislodge the fragment and bind irreversibly.  This would more or less account for the 
kinetics; when the fragment was at high enough concentration, the CAMP factor would 
initially saturate with fragment but then get rid of it by interacting with each other.  
There was no hemolytic inhibition was observed with CAMP1-56 even at a 
concentration up to 200 μg/mL, which suggested that it was not capable of competing 
membrane receptor and lost its oligomerization ability on both sides.  
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 WT 1ug/mL CAMP114-226 2ug/mL
 WT 1ug/mL CAMP114-226 4ug/mL
 WT 1ug/mL CAMP114-226 8ug/mL
 WT 1ug/mL CAMP114-226 16ug/mL
 WT 1ug/mL CAMP114-226 32ug/mL







Figure 3. 9 Hemolytic titration of CAMP factor incubated with CAMP114-226. 
The 50% hemolysis was achieved by CAMP factor (1 μg/mL) in 15 minutes.  With co-
incubation of CAMP114-226 at the concentration of 8 μg/mL, the 50% hemolysis was 
achieved in 20 minutes; with co-incubation of CAMP114-226 at the concentration of 16, 32 
and 64 μg/mL, the 50% hemolysis was achieved in 30 minutes. Sphingomyelinase-treated 
sheep erythrocytes (0.5% v/v) were used. The CAMP factor concentration was 1 μg/mL. 
 
3.6 Membrane Binding competition   
CAMP114-226 inhibited the hemolysis of intact CAMP factor, though it is not clear if it 
was due to the competition for membrane receptor binding. In the binding competition 
assay, 1 μg/mL of labelled CAMP factor (F109C) was incubated with CAMP114-226 at 
concentrations of 4, 8, 16, and 32 μg/mL and sphingomyelinase-treated ghost membranes 
(equivalent to 0.5 %( v/v) blood cells). The fluorescein emission was recorded after all 
unbound proteins had been removed (Figure 3.10). With increasing concentrations of 
CAMP114-226, the emission remained unchanged, indicating that binding was unaffected; 
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the reduced rate of hemolysis therefore must indeed be related to an inhibition of 
oligomerization rather than binding.  








 F109C 1ug/mL, CAMP114-226 4ug/mL
 F109C 1ug/mL, CAMP114-226 8ug/mL
 F109C 1ug/mL, CAMP114-226 16ug/mL


















Figure 3. 10 Emission spectra of fluorescein labeled CAMP factor F109C. 
It was incubated with CAMP114-226 at different concentrations for 20 minutes. 
 
From the experiments done before, the general abilities of all the fragments are 
summarized in Table 3.2. The relative positions of CAMP factor fragments were compared 
with the transmembrane prediction plot obtained from the on-line program “DAS TM-
segment prediction” at http://www.sbc.su.se/~miklos/DAS/ (Figure 3.11). The peak 
regions in the plot are the possible transmembrane regions. The region between 104 and 
113 was previously identified as transmembrane region [56, 63].  
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Table 3. 2 The general abilities of CAMP factor fragments 
 
 








CAMP factor Yes 15 min at 1μg/mL Yes -- -- -- 
CAMP1-56 
          
No -- Yes 40.1±1.1% No -- 
CAMP1-113 
 
Yes 30 min at 400μg/mL Yes 11.3±0.8% -- -- 
CAMP1-170 
 
Yes 15 min at 100μg/mL Yes 14.8±0.7% -- -- 
                                       CAMP171-226    
                                              
Yes 10 min at 400μg/mL Yes 32.5±1.2% -- -- 
                                       CAMP114-226 
                             
No -- Yes 28.4±0.8% Yes No 
                                        CAMP57-226     
                 






























Figure 3. 11 Relative positions of CAMP factor fragments. 
The relative positions of the CAMP factor fragments were compared with a CAMP factor 
transmembrane prediction graph. The previously identified transmembrane region is 
labeled between 104 and 113.  
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3.7 Unknown protein    
  
Before the CAMP171-226 was purified under denaturing conditions, it was eluted with an 
unknown protein with a size of around 66 kDa, which was suspected as an octamer of 
CAMP171-226. These two species were separated by gel filtration and analyzed by mass 
spectrometry (Figure 3.8). The possibility that the unknown protein might be an octamer 
was thereby eliminated. Nevertheless, the unknown protein was observed to have 
hemolytic activity to sphingomyeliase-treated sheep blood cells (Figure 3.12). 
+ESI in 50/50:MeCN/water + 0.2% FA
mass












ESI+ 50/50:MeCN/H2O + 0.2% FA
mass













Figure 3. 12 Mass spectra of CAMP171-226 and an unknown protein. 
A. The unknown protein (68978.5 Da). B. CAMP171-226 ( 8232 Da) 
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3.8 Discussion  
 
Streptococcus agalactiae CAMP factor, a membrane pore-forming toxin, is considered 
to have the same action mechanism as other PFTs: binding, oligomerization, and 
membrane insertion. With many PFTs, these functions reside in specific regions of the 
molecule. The studies on CAMP factor mutant (CAMPW167F) done by our former lab 
member (Shanshan Liu) have shown that CAMPW167F could bind to sphingomyelinase-
treated sheep erythrocyte membrane but suffered a significant loss in hemolytic activity 
[56]. This finding indicates that CAMP factor could have specific regions for the different 
stages during pore-formation. 
To reveal the regions responsible for these functions, six CAMP factor fragments, 
CAMP1-56, CAMP57-226, CAMP1-113, CAMP114-226, CAMP1-170, and CAMP171-226, were 
constructed using site-specific mutagenesis. After protein purification, these fragments 
were all subject to hemolytic titration. Fragments CAMP1-56 and CAMP114-226 showed no 
hemolytic activity. The other fragments showed different levels of hemolytic activity. 
Among them, CAMP57-226 and CAMP1-170 showed the strongest activity; they could 
achieve 50% hemolysis in 15 minutes at a concentration of 12.5 μg/mL and 100 μg/mL 
respectively. 
From this activity comparison, the most active fragments have sequence overlapping 
between residues 57 and 170. A little activity was shown in fragment CAMP1-113, so 
residues 57-113 seem to be absolutely essential; adjoining regions, particularly those at the 
C-terminus, contribute a lot.  
 From hydrophobicity predictions, this region contains the most likely membrane 
inserted regions. From the cysteine-scanning mutagenesis studies done by Shanshan Liu 
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and David Donkor, this region is involved in membrane insertion [56, 63]. This probably 
explained the much higher activity for   CAMP1-170 and CAMP57-226.  
Fragments CAMP1-56 and CAMP114-226, that do not show activity, were shown to be 
able to bind to cell membranes. The membrane binding could be examined using SDS-
PAGE, however, the interference caused by membrane proteins could be very strong, 
particularly for small fragments and fragments with low binding efficiency. By using 
fluorometric method, the membrane binding efficiency was quantitatively measured with 
fluorescein-labelled fragments. The membrane binding efficiency of the haemolytically 
inactive CAMP114-226 (28.4±0.8%) was shown to be even higher than that of the slightly 
active CAMP1-113 (11.3±0.8%). These binding results suggested these two fragment are 
lacking either oligomerization or insertion ability. Chemical cross-linking assay was 
performed on both fragments, however, neither of them showed oligomerization. 
Within an oligomer of rotational symmetry, each subunit must expose two distinct and 
contact surfaces that interact with the complemenrary surfaces on neighbouring subunits. 
In a fragment that has lost the ability to oligomerize, either or both contact surfaces may be 
affected. If only one surface were affected, the fragment should still be able to associate 
with intact proteins one side and thereby inhibit the further progress of oligomerization and 
therefore hemolysis. 
Both CAMP1-56 and CAMP114-226 were assayed for their ability of inhibiting hemolysis 
of CAMP factor. CAMP1-56 did not show any inhibition of hemolysis. In contrast, 
CAMP114-226 showed inhibition that increased up to a concentration of 16μg/mL. Beyond 
that concentration, the extent of inhibition levelled off. 
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The inhibition of hemolysis observed with CAMP114-226 might be caused by 
oligomerization termination or, alternatively, by competition for membrane receptors. The 
membrane binding competition was assayed, which ruled out the second possibility. 
Inhibition levelled off beyond the concentration of 16μg/mL could be caused by the 
weak interaction between fragement and intact protein. When the fragment concentration 
was higher than 16μg/mL, all the intact CAMP factor protein was associated with the 
fragments, which gave the saturated inhibition level. The interaction between intact CAMP 
factor is stronger, which allows the fragment-associated CAMP factor to oligomerize each 
other after dislodging the fragment.  
The weak hemolytic activity from CAMP171-226 was unexpected comparing to 
hemolytic inactive CAMP114-226.  
All the fragments were shown to have membrane binding ability and their binding 
efficiency were measured; the binding efficiency of the hemolytic inactive fragments 
CAMP1-56 (40.1±1.1%) and CAMP114-226 (28.4±0.8%) are higher than the hemolytic 
fragments CAMP1-170 (14.8.±0.7%) and CAMP1-113 (11.3±0.8%). Therefore the binding 
ability resides in a region that separated from those for oligomerization and insertion. 
Among the hemolytic fragments, the more active fragments also showed higher membrane 
binding efficiency.  
From this study, CAMP factor is shown again to have conserved regions for different 
functions. The region between residues 57 and 113 in CAMP factor is critical for 
completing hemolysis, which is involved in membrane insertion. The fragments lacking 
this region have partial or no oligomerizing ability, suggested that it was also responsible 
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for complete oligomerization. The high binding efficiency of CAMP114-226 showed that the 
major binding domain resides in this region.  
 
 
3.9 Future studies  
To elucidate the detailed information about the regions responsible for all the action 
stages, more CAMP factor fragments could be obtained by the same method and assayed 
for their ability. 
For the hemolytic fragments, they will be tested for their activity on liposomes 
enclosing calcein. The pores formed by these fragments will be studied by osmotic 
protection by PEG, and electron microscopy to compare with CAMP factor.  
CAMP factor has been shown to bind to GPI-anchored protein [22, 64], the further 
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A 1: Hemolytic titration of CAMP factor fragments 
 








































































































































A 2: Membrane binding of CAMP factor fragment 
 







 C A M P 57-226
 C A M P 57-226 incu bated  w ith  m em brane
























100  C A M P
1-170 incubated w ith m em brane
 C A M P 1-170


























 CA M P171-226 incubated w ith m em brane
 CA M P171-226



























 C A M P 1-113 incubated w ith  m em brane
 C A M P 1-113

























 M em brane
 CA M P114-226 incubated w ith m em brane
 CA M P114-226
R
el
at
iv
e 
em
is
si
on
 in
te
ns
ity
W avelength (nm)
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 62
